Published in Biochem J on October 15, 2008
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 3.37
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med (2015) 2.88
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res (2008) 2.34
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov (2015) 2.07
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol (2013) 1.88
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res (2015) 1.61
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract (2012) 1.34
Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc Natl Acad Sci U S A (2013) 1.25
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia (2013) 0.90
Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Contemp Oncol (Pozn) (2012) 0.89
Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships. BMC Genomics (2015) 0.81
Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study. J Mol Model (2015) 0.77
Differences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutants. PLoS One (2013) 0.76
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. PLoS Med (2017) 0.75
JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines. Mol Cancer Ther (2017) 0.75
Proteomic analysis of human neutrophil granules. Mol Cell Proteomics (2005) 1.81
Differences in solute removal by two high-flux membranes of nominally similar synthetic polymers. Nephrol Dial Transplant (2007) 1.51
Ensuring patient safety: what lessons can be learned from device-related adverse events in hemodialysis? Artif Organs (2002) 1.38
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem (2014) 1.36
The actin cytoskeleton regulates exocytosis of all neutrophil granule subsets. Am J Physiol Cell Physiol (2007) 1.16
Comparison of proteins expressed on secretory vesicle membranes and plasma membranes of human neutrophils. J Immunol (2008) 1.11
PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell Signal (2009) 1.10
Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant (2013) 1.08
Granule exocytosis contributes to priming and activation of the human neutrophil respiratory burst. J Immunol (2011) 1.08
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene (2004) 1.02
Heat shock protein 27 regulates neutrophil chemotaxis and exocytosis through two independent mechanisms. J Immunol (2007) 1.02
Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant (2010) 1.00
Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats. Shock (2013) 0.97
Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils. J Immunol (2005) 0.92
Tumour invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol (2005) 0.88
Counterregulation of clathrin-mediated endocytosis by the actin and microtubular cytoskeleton in human neutrophils. Am J Physiol Cell Physiol (2009) 0.88
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem (2012) 0.88
Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem (2015) 0.85
ROCK1 and LIMK2 interact in spread but not blebbing cancer cells. PLoS One (2008) 0.83
Identification of phosphoproteins associated with human neutrophil granules following chemotactic peptide stimulation. Mol Cell Proteomics (2010) 0.81
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol (2010) 0.80
Proteomic analysis of human neutrophils. Methods Mol Biol (2006) 0.80
Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant (2007) 0.80
Enzymatic characterisation of USP7 deubiquitinating activity and inhibition. Cell Biochem Biophys (2011) 0.80
Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode. J Chem Inf Model (2010) 0.79
Anti-proteinase 3 antibodies both stimulate and prime human neutrophils. Nephrol Dial Transplant (2008) 0.77
Exocytosis of neutrophil granule subsets and activation of prolyl isomerase 1 are required for respiratory burst priming. J Innate Immun (2013) 0.77
Technical note: proteomic approaches to fundamental questions about neutrophil biology. J Leukoc Biol (2013) 0.77
Dialysate ... Ho-hum! Clin J Am Soc Nephrol (2009) 0.76
Dialysate quality: new standards require a new approach to compliance. Semin Dial (2012) 0.76
Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5). J Med Chem (2009) 0.76
Re: Cohn et al. Semin Dial (2005) 0.75
Should dialysis modalities be designed to remove specific uremic toxins? Semin Dial (2009) 0.75
The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach. Bioorg Med Chem Lett (2011) 0.75
The conditional kinase DeltaMEKK1:ER* selectively activates the JNK pathway and protects against serum withdrawal-induced cell death. Cell Signal (2005) 0.75
Water treatment for hemodialysis: ensuring patient safety. Semin Dial (2002) 0.75
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. J Chem Inf Model (2017) 0.75
Ultrapure dialysate for home hemodialysis? Adv Chronic Kidney Dis (2007) 0.75
Identification and characterisation of dual inhibitors of the USP25/28 Deubiquitinating enzyme subfamily. ACS Chem Biol (2017) 0.75